2022 Genitourinary Cancers Symposium

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps.

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions.

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

David VanderWeele comments on the PROpel and MAGNITUDE trials investigating the addition of a PARP inhibitor to abiraterone in men with metastatic castration-resistant prostate cancer, focusing on the differences between the studies and the unanswered questions.

Petros Grivas explains why sacituzumab govitecan plus pembrolizumab – investigated in cohort 3 of the TROPHY-U-01 study comprising metastatic urothelial cancer patients with progression after platinum-based treatment – is not ready for prime time, but merits further investigation in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany